Core Viewpoint - The company has entered into a licensing agreement with Eisai Co., Ltd., granting Eisai exclusive rights to commercialize the product Hansizhuang® (sulrurolizumab injection) in a specified region and field [1] Group 1: Financial Terms - Eisai will pay an upfront fee of $75 million to the company [1] - Regulatory milestone payments could total up to $80.01 million, contingent on the achievement of various regulatory milestones for the licensed product in the region [1] - Commercial sales milestone payments could reach up to $233.33 million, based on the annual net sales levels of the licensed product in the region [1] - The company will receive royalties calculated as a double-digit percentage of the annual net sales of the licensed product in the region [1]
复宏汉霖：与Eisai公司签订许可协议 将获得首付款7500万美元